TP53 and medulloblastoma: Cavalli et al. [26] identified four main subtypes of SHH-activated medulloblastoma, along with their main mutations and age groups: SHH-α, typical of 3–16-year-old patients, has the worst prognosis among this group and harbors TP53 mutations in one-third of the cases; SHH-β and SHH-γ groups are more prevalent in infants (1.3 and 1.9 years of age, respectively), with SHH-β displaying a poorer prognosis compared to SHH-γ due to increased rate of metastatic dissemination.